异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效

目的 探讨沙丁胺醇与布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效。方法 选取2017年7月~2019年4月我院收治的慢阻肺急性加重期患者94例，根据随机数字表法分为观察组和对照组，每组47例。对照组给予沙丁胺醇与布地奈德雾化吸入治疗，观察组在对照组基础上加用异丙托溴铵雾化吸入治疗，比较两组临床疗效、不良反应总发生率及治疗前后肺功能指标变化情况（FEV1%、FEV1和FVC）。结果 观察组总有效率为91.49%，高于对照组的74.47%，差异有统计学意义（P＜0.05）。观察组不良反应总发生率为12.76%，低于对照组的14.89%，但差异无统计学意义（P＞0.05）。治疗后，观察组FEV1%、FEV1和FVC均高于对照组[（70.61±14.74）% vs（61.24±13.42）%]、[（2.25±0.77）L vs（1.94±0.63）L]、[（3.46±0.98）L vs（3.07±0.91）L]，差异有统计学意义（P＜0.05）。结论 沙丁胺醇与布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期患者疗效显著，有助于改善患者临床症状及肺部通气功能，减少用药后不良反应发生几率，安全性高。

Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Objective To investigate the clinical efficacy of salbutamol and budesonide combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 94 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital from July 2017 to April 2019 were enrolled. The patients were divided into observation group and control group according to the random number table method, with 47 cases in each group. The control group was given salbutamol and budesonide inhalation treatment. The observation group was treated with ipratropium bromide inhalation treatment on the basis of the control group. The clinical efficacy, the total incidence of adverse reactions and the changes of lung function indexes before and after treatment were compared between the two groups. Situation (FEV1%, FEV1 and FVC).Results The total effective rate of the observation group was 91.49%, which was higher than that of 74.47% in the control group,the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was 12.76%, which was lower than that of 14.89% in the control group, but the difference was not statistically significant (P>0.05). After treatment, FEV1%, FEV1 and FVC in the observation group were higher than those in the control group [(70.61±14.74)% vs (61.24±13.42)%], [(2.25±0.77) L vs (1.94±0.63) L], [( 3.46±0.98) L vs (3.07±0.91) L], the difference was statistically significant (P<0.05).Conclusion Salbutamol combined with budesonide and ipratropium bromide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease is effective, which can improve the clinical symptoms and pulmonary ventilation function, reduce the incidence of adverse reactions after medication, and have high safety.